Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis

Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland.
The Lancet (Impact Factor: 45.22). 12/2008; 373(9659):240-9. DOI: 10.1016/S0140-6736(08)61762-6
Source: PubMed

ABSTRACT WHO and Health Action International (HAI) have developed a standardised method for surveying medicine prices, availability, affordability, and price components in low-income and middle-income countries. Here, we present a secondary analysis of medicine availability in 45 national and subnational surveys done using the WHO/HAI methodology.
Data from 45 WHO/HAI surveys in 36 countries were adjusted for inflation or deflation and purchasing power parity. International reference prices from open international procurements for generic products were used as comparators. Results are presented for 15 medicines included in at least 80% of surveys and four individual medicines.
Average public sector availability of generic medicines ranged from 29.4% to 54.4% across WHO regions. Median government procurement prices for 15 generic medicines were 1.11 times corresponding international reference prices, although purchasing efficiency ranged from 0.09 to 5.37 times international reference prices. Low procurement prices did not always translate into low patient prices. Private sector patients paid 9-25 times international reference prices for lowest-priced generic products and over 20 times international reference prices for originator products across WHO regions. Treatments for acute and chronic illness were largely unaffordable in many countries. In the private sector, wholesale mark-ups ranged from 2% to 380%, whereas retail mark-ups ranged from 10% to 552%. In countries where value added tax was applied to medicines, the amount charged varied from 4% to 15%.
Overall, public and private sector prices for originator and generic medicines were substantially higher than would be expected if purchasing and distribution were efficient and mark-ups were reasonable. Policy options such as promoting generic medicines and alternative financing mechanisms are needed to increase availability, reduce prices, and improve affordability.

Download full-text


Available from: Dennis Ross-Degnan, Oct 19, 2014
  • Source
    • "Poor availability, low affordability and high medicines prices are important barriers to access to essential medicines in many low-and middle-income countries [4]-[8]. A review of data from 36 low-and middle-income countries showed that in the public sector availability ranged from 29% to 54% and private sector patients paid 9 to 25 times international reference prices (IRP) for lowest-priced generic products [9]. "
    Open Access Library Journal 01/2015; 02(01):1-10. DOI:10.4236/oalib.1100983
  • Source
    • "According to this study the availability of EDs in JHC was 55.65%. An investigation conducted by WHO on medicine price, availability and affordability in 36 developing and middle income countries indicates that the availability of generic medicines in public sectors ranges form 29.4% to 54.4% (Cameron et al., 2009). Compared to this the availability of drugs in JHC pharmacy it is slightly higher. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Essential drugs (EDs) satisfy the priority health care needs of a population and their availability and affordability at all times is crucial for provision of complete health service. The study aimed to assess availability and affordability of treatment cost for common diseases in Jimma Health Center (JHC). A cross sectional study was conducted using structured data abstraction form for exit interviews and checklists. Only 128 (55.65%) EDs were available. The average price for commonly used drugs per recommended dose for an individual patient in JHC Pharmacy, Ethiopian Red Cross (ERC) Pharmacy and Private Pharmacies were $0.65, $0.62 and $0.94 respectively. Affordability of medications was significantly associated with age, marital status, occupational status, gross monthly income and number of economically dependent family members (p<0.005). 58.07% of the respondents bought drugs from JHC pharmacy, while the rest bought drugs from ERC pharmacy and private retail outlets. In this study 47.83%, 33.54% and 18.63% of the respondents said that the drugs are not affordable, fairly affordable and affordable respectively. Low availability of EDs forced patients to purchase drugs from private pharmacies, go to informal sector or forgo treatment. Considering proportion of total household income spent on health care, costs of treatment seem unaffordable.
    Journal of Applied Pharmaceutical Science 10/2013; 3(10):101-105. DOI:10.7324/JAPS.2013.31017 · 0.47 Impact Factor
  • Source
    • "It is the most frequently used pricing policy in Europe (in 2012, 24 European countries excluding Denmark, Sweden and United Kingdom [7] [8] [9] [10]). All of these factors may lead to a magnitude of differences in prices of medicines [11] [12] [13] [14] [15] [16] [17]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies have suggested that medicines prices in Europe converge over time as a result of policy measures such as external price referencing. To explore whether ex-factory prices of on-patented medicines in Western European countries have converged over a recent period of time. Prices of ten on-patent medicines in five years (2007, 2008, 2010, 2011, 2012) of 15 European countries were analyzed. The unit of analysis was the ex-factory price in Euro per defined daily dose (exchange rate indexed to 2007). A score (deviation from the average price) per country as well as the ranges were calculated for all medicines. The prices between countries and selected products varied to a great extent from as low as an average price of €1.3/DDD for sitagliptin in 2010-2012 to an average of €221.5/DDD for alemtuzumab in 2011. Between 2008 and 2012, a price divergence was seen which was fully driven by two countries, Germany (up to 27% more expensive than the average) and Greece (up to 32% cheaper than the average). All other countries had stable prices and centered around the country average. Prices of less expensive as well as expensive medicines remained relatively stable or decreased over time, while only the price of sirolimus relatively increased. Our study period included the time of the recession and several pricing policy measures may have affected the prices of medicines. Instead of the expected price convergence we observed a price divergence driven by price changes in only two of the 15 countries. All other European countries remained stable around the country average. Further research is needed to expand the study to a bigger sample size, and include prescribing data and Eastern European countries.
    Health Policy 09/2013; 112(3). DOI:10.1016/j.healthpol.2013.08.012 · 1.73 Impact Factor
Show more